fashion -WSS

fashion

author：explore 2025-08-30 19:12:45 - browse：6

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： With FDA staff opposed to Sarepta therapy, top official intervened

WSS

'A game

Neurocrine congenital adrenal hyperplasia trial succeeds

People with substance use disorder deserve online privacy

Why are elite athletes different? Take a look at their microbes

In areas with more Black doctors, Black people live longer

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

What would happen to your eyes if you looked at the solar eclipse?

Activists slam private health insurers over coverage restrictions

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Neurocrine congenital adrenal hyperplasia trial succeeds

Novavax promises a turnaround & Lilly roils the obesity market

Donald Trump's relentless attacks on special counsel Jack Smith

Continuity nursing helped my family in our darkest PICU moments

Chamber of Commerce, DOJ clash in court over drug prices

focus

3 hurdles to bringing medical devices to the U.S. market

FDA weighs limits of animal data in assessing artificial wombs

Paxlovid study fails to answer questions over benefit for broader groups

Weight bias in eating disorder treatment complicated by new weight loss drugs

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

David Liu startup to focus on CRISPR delivery

hotspot

explore

leisure time

entertainment